EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Friday, June 14th 2019 at 1:02pm UTC WALTHAM, Mass.–(BUSINESS WIRE)– Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of Directors. During a career of nearly …
Plus »CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
Saturday, June 15th 2019 at 11:00am UTC An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND …
Plus »PURE Bioscience Reports Fiscal 2019 Third Quarter and Nine-Month Financial Results
Thursday, June 13th 2019 at 8:05pm UTC Update on SDC-Based Antimicrobial Food Safety Solutions SAN DIEGO–(BUSINESS WIRE)– PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2019. Q3: Summary …
Plus »bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent ?-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress
Friday, June 14th 2019 at 9:31am UTC Up to 3.8 years of transfusion independence in Phase 1/2 Northstar (HGB-204) study in patients with TDT who do not have a ?0/?0 genotype Four of five evaluable patients achieved transfusion independence in ongoing Phase 3 Northstar-2 (HGB-207) study of patients with TDT …
Plus »New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients
Thursday, June 13th 2019 at 8:30pm UTC Findings from head-to-head Early AMPLE study are consistent with earlier studies, adding to body of research showing differences between mechanisms of biologic therapies Results suggest that a genetic marker linked to autoantibody production and a more severe RA disease course – “Shared Epitope” …
Plus »Positive Phase 3 Extension Data for ULTOMIRIS® (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress
Friday, June 14th 2019 at 10:30am UTC – ULTOMIRIS demonstrated consistent efficacy and safety through 52 weeks, with no cases of breakthrough hemolysis (BTH) associated with incomplete C5 complement inhibition – – Nearly all surveyed patients preferred ULTOMIRIS over SOLIRIS® (eculizumab) – BOSTON–(BUSINESS WIRE)– Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced …
Plus »Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)
Friday, June 14th 2019 at 10:00am UTC EDP-938 achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo Conference call and webcast to discuss the data at 8:30 a.m. ET today WATERTOWN, Mass.–(BUSINESS WIRE)– Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused …
Plus »LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis
Friday, June 14th 2019 at 11:00am UTC In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today presented positive results from the Phase IIIb DIALIZE trial which investigated the efficacy and safety of LOKELMA (sodium zirconium …
Plus »Baxter Leads Hemodialysis Research Consortium for German Federal Ministry of Education and Research
Friday, June 14th 2019 at 1:00pm UTC Research aimed at improving health-related, quality-of-life outcomes for hemodialysis patients Novel exploration of anticoagulant-free hemodialysis will investigate expanding function of dialysis membranes World-class Baxter research and development team in Hechingen, Germany, to lead consortium DEERFIELD, Ill.–(BUSINESS WIRE)– Baxter International Inc. (NYSE:BAX), a global …
Plus »Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors
Friday, June 14th 2019 at 2:45pm UTC Ms. Burstein brings significant experience in finance for publicly-traded biotechnology companies BEDFORD, Mass.–(BUSINESS WIRE)– Stoke Therapeutics, Inc., a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment …
Plus »
